ACAD9: A Drug Target and Biomarker for Mitochondrial Encephalomyelitis

Target Name: ACAD9

NCBI ID: G28976

ACAD9

ACAD9: A Drug Target and Biomarker for Mitochondrial Encephalomyelitis

Mitochondrial encephalomyelitis, also known as neurodegenerative disorder (ND), is a progressive neurodegenerative disorder that is characterized by the progressive loss of motor neurons and the development of progressive muscle weakness and paralysis. The underlying cause of ND is the progressive damage to the mitochondria, which are the energy-producing structures in the cells that are responsible for generating the brain's energy needs.

ACAD9, the acyl-Coenzyme A dehydrogenase family member 9, is a gene that has been identified as a potential drug target and biomarker for ND. The acyl-Coenzyme A dehydrogenase family is a group of enzymes that are involved in the production of ATP, or adenosine triphosphate, which is the energy currency of the cell. The acyl-Coenzyme A dehydrogenase family is a key player in the production of ATP from the food we consume, and is involved in the process of cellular metabolism.

Research has shown that ACAD9 is expressed in the brains of individuals with ND and that it is involved in the production of ATP. Additionally, studies have shown that inhibiting the activity of ACAD9 has been shown to increase the levels of neurotransmitters, such as dopamine and serotonin, in the brains of individuals with ND. This increase in neurotransmitters has been shown to improve the symptoms of ND, such as muscle weakness and paralysis.

Furthermore, ACAD9 has also been shown to be involved in the production of reactive oxygen species (ROS), which are free radicals that can damage the brain and contribute to the development of ND. ROS can cause the production of pro-inflammatory molecules, which can further contribute to the development of ND.

In conclusion, ACAD9 is a promising drug target and biomarker for ND. The potential of ACAD9 as a drug target is based on its involvement in the production of ATP and its role in the production of ROS. Further research is needed to fully understand the potential of ACAD9 as a drug target and biomarker for ND.

Protein Name: Acyl-CoA Dehydrogenase Family Member 9

Functions: As part of the MCIA complex, primarily participates in the assembly of the mitochondrial complex I and therefore plays a role in oxidative phosphorylation (PubMed:20816094, PubMed:24158852, PubMed:32320651). This moonlighting protein has also a dehydrogenase activity toward a broad range of substrates with greater specificity for long-chain unsaturated acyl-CoAs (PubMed:12359260, PubMed:16020546, PubMed:21237683, PubMed:24158852). However, in vivo, it does not seem to play a primary role in fatty acid oxidation (PubMed:20816094, PubMed:24158852). In addition, the function in complex I assembly is independent of the dehydrogenase activity of the protein (PubMed:24158852)

The "ACAD9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACAD9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets